FDA Approves First Oral GLP-1 Medication for Chronic Weight Management
The FDA has approved a higher-dose oral semaglutide formulation for obesity treatment, marking the first oral GLP-1 receptor agonist approved specifically for chronic weight management in adults with a BMI of 30 or higher.
GLP-1 Use Associated with 40% Lower Risk of Alzheimer's Disease in Large Study
Researchers analyzing electronic health records from 1.2 million patients found that GLP-1 receptor agonist users had a 40% lower incidence of Alzheimer's disease diagnosis over a 10-year follow-up period.
Medicare Part D Now Covers GLP-1 Medications for Obesity Without Diabetes
CMS finalized a rule expanding Medicare Part D coverage for GLP-1 receptor agonists prescribed for obesity, regardless of diabetes status, potentially benefiting 3.4 million beneficiaries starting January 2027.
Telehealth GLP-1 Prescriptions Surge 340% as Regulatory Barriers Ease
Online prescribing platforms report record demand for GLP-1 consultations following DEA rule changes that permanently allow telehealth prescribing of non-controlled medications without prior in-person visits.
Compounded Semaglutide Shortage Ends as FDA Removes Drug from Shortage List
The FDA officially removed semaglutide from its drug shortage list, signaling that compounding pharmacies must phase out compounded versions by mid-2026 as branded supply normalizes.
FLOW Trial: Semaglutide Reduces Kidney Disease Progression by 24%
The FLOW trial demonstrated that semaglutide significantly reduced the risk of major kidney disease events in patients with type 2 diabetes and chronic kidney disease, expanding the drug's clinical utility.